Geographic Atrophy Treatment Market By Diagnosis (Fundus Autofluorescence (FAF), Optical Coherence Tomography Angiography (OCT-A), and Multifocal Electroretinography (mfERG)), By Clinical trials (Phase III, Phase II, Phase I and Preclinical), By End User (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, and Others), and Geography

Purchase Option

$ 4400
$ 6600
$ 8900

Geographic Atrophy Treatment Market size was valued at USD 32.6 Billion in 2022 and is anticipated to reach USD 68.5 Billion by 2029, growing at a CAGR of 11.2%  from 2023 to 2029. Geographic atrophy (GA) is a chronic progressive degeneration of the macula, as part of late-stage age-related macular degeneration (AMD). The disease is characterized by localized sharply demarcated atrophy of outer retinal tissue, retinal pigment epithelium, and choriocapillaris. the rapidly growing geriatric population and high demand for effective treatment options influence the market growth. According to the American Academy of Ophthalmology, over 8 million people are affected worldwide with GA, approximately 20% of all individuals with AMD. The incidence of GA is expected to rise as the age burden of developed countries is increasing. The several risk factors associated with geographic atrophy, it is shown in the geriatric population the high rate of prevalence, and emerging novel treatment options drive the market growth. Advances in healthcare technology and focus on research and development activities accelerate the market growth, and the numerous incidences result in high demand for novel drugs creating lucrative opportunities in the market. Furthermore, the lack of focus on visual restoration and the failure of investigational drugs limits the market growth. In addition, limited knowledge about geographic atrophy hinders market growth. it is predicted that in the following years, increasing health awareness and growing healthcare infrastructure boost the market growth. By regional analysis, North America held the major market share in 2022 and is expected to dominate the global Geographic Atrophy Treatment market due to the rise in the incidence of retinal diseases and surging spending on healthcare development contribute to the market growth in the forecast years.

Geographic Atrophy Treatment Market Summary

Study Period


Base Year




Largest Market

North America

Fastest Growing Market

Asia Pacific
Geographic Atrophy Treatment Market Dynamics

The increasing prevalence of dry muscular degeneration across the world is the major market driver in the Geographic Atrophy Treatment Market during the forecast period. Dry muscular degeneration is a common eye disorder among people over 50 years, it causes blurred eye vision due to the breaking down of the inner layer of the macula, the rapidly increasing geriatric population demands effective treatment options, FDA and Other Drugs regulatory authorities are continuous focusing on clinical trials of the geography atrophy treatment drugs to develop patient-friendly dosage, overall contributing to treatment drive the market growth with significant growth.

Geographic Atrophy Treatment Market Segmentation

By Diagnosis
  • Fundus Autofluorescence (FAF)
  • Optical Coherence Tomography Angiography (OCT-A)
  • Multifocal Electroretinography (mfERG)
By Clinical Trials
  • Phase III
  • Phase II
  • Phase I
  • Preclinical
By End User
  • Hospitals
  • Ambulatory Surgical Centres
  • Diagnostic Centres
  • Others
By Geography
  • North America
  • Europe
  • The Asia Pacific
  • Latin America
  • MEA

Frequently Asked Questions

The Geographic Atrophy Treatment Market size was valued at USD 32.6 Billion in 2022 and is anticipated to reach USD 68.5 Billion by 2029

The Geographic Atrophy Treatment Market is poised to grow at a significant CAGR of 11.2% from 2023 to 2029.

The leading players in the Geographic Atrophy Treatment Market are Allergan, Hemera Biosciences, Roche, Iveric Bio, NGM Biopharmaceuticals, Allegro Ophthalmics, Alkeus Pharmaceuticals, Gensight Biologics, AstraZeneca, Stealth BioTherapeutics, Gyroscope Therapeutics, Apellis Pharmaceuticals, Lineage Cell Therapeutics, and Regenerative Patch Technologies

Historic years considered for the market study are 2018 through 2022, 2022 is considered as the base year for market estimation and Seven years forecast is presented from 2023 – 2029.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
  • Allergan
  • Hemera Biosciences
  • Roche
  • Iveric Bio
  • NGM Biopharmaceuticals
  • Allegro Ophthalmics
  • Alkeus Pharmaceuticals
  • Gensight Biologics
  • AstraZeneca
  • Stealth BioTherapeutics
  • Gyroscope Therapeutics
  • Apellis Pharmaceuticals
  • Lineage Cell Therapeutics
  • Regenerative Patch Technologies

Adjacent Markets